Sam Murphy

Sam currently serves as VP and Head of International Business Development for Salubris Pharmaceuticals and its US subsidiary SalubrisBio. Prior to joining Salubris, Sam worked for ten years in strategy consulting and transaction advisory services across several global firms including IMS (now IQVIA) and Simon-Kucher & Partners. Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on pricing and market access. He has also supported early-stage financing for emerging pharma/biotech companies. Sam is currently a Board Member of GO Therapeutics and Viracta Therapeutics, as well as a Board Observer at Mercator Medsystems.